The horizon for cancer immunotherapy has been widened by recent acquisitions on the biology of dendritic cells and by research on the role of T regulatory cells in cancer immune escape. Brain tumors are an excellent arena for the development of this progress. Malignant gliomas, in particular, are the object of novel trials that have as a background the initial experience gained with dendritic cell immunotherapy. Moreover, new insights on the role of cancer stem-like cells in glioma development may help defining more specific targets for clinically relevant immune responses.
SCIENTIFIC AND ORGANIZING COMMITTEE
Gaetano Finocchiaro, Lucia Cuppini, Serena Pellegatta (Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta", Milan, Italy)
Sabrina Frata (SEMM, Milan, Italy)
Alessandra Giovannini, Elena Torchiana (Miltenyi Biotec S.r.l, Milan, Italy)